Associate Professor; Translational science laboratory at OSU-James CCC focused on researching immunotherapy in pancreatic and lung cancer
Columbus, OH
Joined July 2017
- Tweets402
- Following279
- Followers383
- Likes950
Thomas Mace, Ph.D. retweeted
🎊 Kudos to Jessica Wedig, @TMaceLab & team for their poster: “CD200-CD200R signaling promotes #myeloid_cell #immune_suppression & reduces #checkpoint blockade efficacy in #PancreaticCancer.” @OhioStatePIIO @OSUCCC_James #SITC2025 #ImmunoOncology
Thomas Mace, Ph.D. retweeted
🎉 Congrats to Ayushi Das, @TMaceLab for presenting their poster at #SITC2025!
🧠✨ “A Novel Mouse Model to Identify Antigen-Specific #Immune Responses in #PancreaticCancer Cachexia”
Proudly representing @OhioStatePIIO @OSUCCC_James 💪 #Biomarkers #ImmuneMonitoring
Thomas Mace, Ph.D. retweeted
What a journey to finally be a PhD 🎉
Couldn't have done it without the amazing @TMaceLab. So many folks @OSUCCC_James & @OhioState made this such a joyride. I will miss Columbus dearly because of all the friends I made here and all the life lessons I learnt! – at Columbus, OH
Thomas Mace, Ph.D. retweeted
Ongoing efforts from our pulmonary team working to understand pulmonary toxicities from cancer #immunotherapy. Need to have better risk stratification, predictors, and treatment for pneumonitis. @OhioStateMedOnc @OSUWexMed
@OSUCCC_James @OhioStateIMRes
academic.oup.com/oncolo/arti…
Thomas Mace, Ph.D. retweeted
Grateful for having beautiful people as lab mates from @TMaceLab with whom I can attend events like 'Women in Oncology' @OSUCCC_James and listen to stalwarts who happen to be awesome women in the field.
Thomas Mace, Ph.D. retweeted
We’re looking forward to #TRCCC ‘24 “Expediting Progress in Cancer Immunotherapy.” Many thanks to the #PIIO’s @RobertBaiocchi & @TMaceLab for their leadership on the TRCCC BoD! Also many thanks to #PIIO recruit @A_Wieland_PhD, who’ll be presenting @ TRCCC. go.osu.edu/CjzZ
Thomas Mace, Ph.D. retweeted
Check out recent pub in @sciencedirect by #PIIO members @dwightowenmd and @TMaceLab who highlight the association between the baseline clearance of immune checkpoint inhibitors (ICIs), cachexia, and outcomes in cancer patients.
go.osu.edu/Ch5D
Thomas Mace, Ph.D. retweeted
Mark your calendars! The TRCCC annual meeting will be held from February 21-23 next year. We look forward to seeing the progress made in cancer #immunotherapy
trccc.org/annual-meeting
Thomas Mace, Ph.D. retweeted
Recent review from the pharmacology team at OSU highlights this important topic in cancer #Immunotherapy. #CancerResearch @OhioStateMedOnc
@OSUCCC_James @TMaceLab
doi.org/10.1158/1078-0432.CC…
Thomas Mace, Ph.D. retweeted
Are you an #OhioState grad student or post-doc interested in learning more about tumor immunology? Join us Spring 2024, as #PIIO member @TMaceLab hosts a seminar entitled, ‘Cancer Immunology: Critical Journal Readings (BSGP 7900).’ For more info, contact Dr. Mace!
Thomas Mace, Ph.D. retweeted
Did some 'non-scientific writing' that got shortlisted for #TheCancerResearcher
Very happy it got published on World Pancreatic Cancer Day #WPCD Please give it a read!
The Choice to Stay in Motion magazine.eacr.org/the-choice…… via @EACRnews
Thomas Mace, Ph.D. retweeted
Hot off the press! Please see our @jitcancer paper! #metformin + #immunotherpay lacks efficacy in MSS #colorectalcancer @BasselElRayesMD @MehmetAkce2 @WinshipAtEmory @ONealCancerUAB #sitc
New #JITC article: Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer bit.ly/3M7tWZ7 @LesinskiLab @MehmetAkce2 @BasselElRayesMD
Thomas Mace, Ph.D. retweeted
Amazing dinner with our @ZCMlab collaborators at @OSUCCC_James @TMaceLab @AshishManne representing #AACRPan23 @OSUWexMed @Pelotonia after having to honor to talk about our obesity and PDAC work. #OSUGHNDIVISION
Thomas Mace, Ph.D. retweeted
Now accepting applications for the Immunology and Immunotherapeutics PhD Graduate Program (I2GP) @OhioStateMed. Come join our growing community of Immunologists and perform leading edge research in top level facilities! @OhioStatePIIO @OSUCCC_James
Apply: gpadmissions.osu.edu/program…
Thomas Mace, Ph.D. retweeted
Combined IL-6/CTLA-4 blockade inhibits pancreatic tumor growth via CXCR3 signaling:buff.ly/3VtT3sn
@LesinskiLab @BwareRedHair @phillipsmaggiej @chrystal_Paulos @hknochelmann
@greeneEMnM @CarsonLabOSU @brobinsonGIpath @TMaceLab @cameron_herting
@anruggieri @BasselElRayesMD
Thomas Mace, Ph.D. retweeted
Do you want a career in cancer immunology and immunotherapy? Do you want to take a leading role in pursuing that career? We study B cells, pancreatic cancer (and others), and want to hear about your ideas. Gunderlab is hiring! DM me.
osu.wd1.myworkdayjobs.com/OS…
Thomas Mace, Ph.D. retweeted
The Immunology & Immunotherapeutics Graduate PhD Program (I2GP) is now accepting applications. Apply now to participate in leading-edge fundamental and translational #immunology research in labs across the @OSUWexMed, MI&I, @OSUCCC_James, & #PIIO. Visit go.osu.edu/i2gp
Thomas Mace, Ph.D. retweeted
The @OhioStateMed has launched the Immunology and Immunotherapeutics Graduate PhD Program (I2GP) focused on cancer immunotherapeutics, systems immunology, host-pathogen interactions, vaccine development, etc. Application opens @ end of August 2022. #PIIO go.osu.edu/i2gp
ALT Collage describing the vibrant research environment at Ohio State University Dept. of Microbial Infection and Immunity and the Comprehensive Cancer Center's Pelotonia Institute for Immuno-Oncology
